Overcoming EGFR-Mediated Dendritic Cell Dysfunction to Enhance Anti-tumor Immunity in EGFR-Mutant NSCLC by Precisely Targeting CD73 With pH-responsive Nanocarriers.
Sign Up to like & getrecommendations! Published in 2025 at "Advanced science"
DOI: 10.1002/advs.202513182
Abstract: EGFR mutations remain a major challenge in immunotherapy for non‐small cell lung cancer (NSCLC), with poor responses to immune checkpoint inhibitors driven by mechanisms associated with EGFR mutation‐mediated tumor microenvironment (TME) modulation. This study reveals… read more here.
Keywords: mutant nsclc; dendritic cell; tumor; cell ... See more keywords
Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC
Sign Up to like & getrecommendations! Published in 2020 at "Translational Oncology"
DOI: 10.1016/j.tranon.2020.100920
Abstract: Highlights • The glutamine utilization of KRAS-mutant NSCLC is higher than that of KRAS wild-type.• Targeted GLS1 and MEK inhibition enhance antitumor activity in vitro and in vivo.• The therapeutic response can be well identified… read more here.
Keywords: mutant nsclc; inhibition; inhibition glutamine; gls1 mek ... See more keywords
HS-10296 (Almonertinib) enhances radiosensitivity in EGFR-mutant NSCLC (including T790M) through inhibition of EGFR downstream signaling and DNA damage repair.
Sign Up to like & getrecommendations! Published in 2025 at "Carcinogenesis"
DOI: 10.1093/carcin/bgaf070
Abstract: Non-small cell lung cancer (NSCLC) harboring EGFR mutations, including the resistant T790M variant, continues to require improved therapeutic strategies despite the development of EGFR tyrosine kinase inhibitors (TKIs). This study evaluates the radiosensitizing potential of… read more here.
Keywords: dna damage; egfr; mutant nsclc; inhibition ... See more keywords
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-18-1542
Abstract: Purpose: Osimertinib was initially approved for T790M-positive non–small cell lung cancer (NSCLC) and, more recently, for first-line treatment of EGFR-mutant NSCLC. However, resistance mechanisms to osimertinib have been incompletely described. Experimental Design: Using cohorts from… read more here.
Keywords: egfr mutant; mutant nsclc; continuation; resistance ... See more keywords
Abstract 4650: High intratumoral levels of Notch3 increase tumorigenesis and promote an immunosuppressive TME in EGFR-mutant NSCLC
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4650
Abstract: Activating mutations in the Epidermal Growth Factor Receptor (EGFR) are one of the most common driver mutations in non-small cell lung cancer (NSCLC). They are present in the tumors of ~15% of Caucasian patients and… read more here.
Keywords: increase; egfr mutant; levels notch3; mutant nsclc ... See more keywords
Abstract 5517: Overcoming sotorasib acquired resistance in KRASG12C mutant NSCLC by TUSC2 gene therapy
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-5517
Abstract: Acquired resistance (AR) to sotorasib, an FDA-approved KRAS inhibitor, poses a significant challenge in treating KRASG12C mutant NSCLC. Despite initial responses, patients invariably develop resistance, necessitating alternative therapeutic strategies. The mechanisms of AR include the… read more here.
Keywords: resistance; therapy; mutant nsclc; sotorasib ... See more keywords
Phase 1 study of the anti-HER3 antibody drug conjugate U3-1402 in metastatic or unresectable EGFR-mutant NSCLC.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps9110
Abstract: TPS9110Background: While outcomes for patients with EGFR-mutant NSCLC have significantly improved with the use of EGFR tyrosine kinase inhibitors, there remain limited treatment options for many pa... read more here.
Keywords: egfr mutant; mutant nsclc; anti her3; study anti ... See more keywords
Spatial transcriptomic profiling of the tumor microenvironment in EGFR and KRAS mutant non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.8539
Abstract: 8539 Background: Immune checkpoint inhibitors have greatly improved outcomes in advanced non-small cell lung cancer (NSCLC). However, patients with EGFR mutant NSCLC have a poor response to immune checkpoint inhibitor therapy. Emerging evidence suggests that… read more here.
Keywords: egfr; tumor microenvironment; mutant nsclc; tumor ... See more keywords
Clinical and molecular features of concomitant EGFR and SMARCA4 mutations in an East Asian cohort.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.e20645
Abstract: e20645 Background: SMARCA4 is a subunit of the SWI/SNF complex and is frequently mutated in non-small cell lung cancer (NSCLC). Recent studies have identified SMARCA4 mutation as a poor prognostic factor in KRAS-mutant NSCLC. Preclinical… read more here.
Keywords: cohort; smarca4; mutant nsclc; concomitant egfr ... See more keywords
EGFR first- and second-generation TKIs—there is still place for them in EGFR -mutant NSCLC patients
Sign Up to like & getrecommendations! Published in 2018 at "Translational cancer research"
DOI: 10.21037/24920
Abstract: Identification of epidermal growth factor receptor (EGFR) as a molecular target has radically changed the treatment of metastatic non-small cell lung cancer (NSCLC) from standard chemotherapy to personalized, targeted therapy. First-, second- and third-generation EGFR… read more here.
Keywords: egfr mutant; mutant nsclc; nsclc patients; first second ... See more keywords
Inhibition of MEK, a canonical KRAS pathway effector in KRAS mutant NSCLC.
Sign Up to like & getrecommendations! Published in 2018 at "Translational lung cancer research"
DOI: 10.21037/tlcr.2018.03.20
Abstract: KRAS mutant NSCLC cells require active nuclear export of Iκβα (also known as NFKBIA), a negative regulatory protein of NF-κB signaling, for maintaining survival signaling (1-3). Nuclear export receptor XPO1 correlates with KRAS mutation status. read more here.
Keywords: inhibition mek; mutant nsclc; canonical kras; kras mutant ... See more keywords